Table 1.

Patient Characteristics

Experiment	Group	No. of Subjects	% Male	Median Age (years) [IQR]	% PDE3i	% PDE5i	% Non-PDEi Inotrope*	% Digoxin	% ACEi	% β-Blocker	% Diuretic
PDE5 Activity	NF	8	62.5	7.7 [2.8–8.9]	0	0	50	0	0	12.5	0
	SV	9	55.6	2.8 [1–3.8]	88.9	22.2	11.1	66.7	77.8	0	77.8
Tissue PDE5 Protein	NF	9	66.7	7.4 [3.2–8.7]	0	0	33.3	0	0	0	0
	SV	7	71.4	2.3 [1.1–2.9]	71.4	14.3	0	57.1	85.7	0	85.7
Tissue PDE5 Histology	NF	1	100	2.9 [n/a]	0	0	100	0	0	0	0
	SV	3	100	2.9 [1.6–7.6]	66.7	33.3	0	100	66.7	0	66.7
NRVM + Serum RT-PCR	NF	5	40	11.5 [7–13.6]	0	0	0	20	0	0	0
	SV	12	58.3	2 [0.9–4.8]	50	33.3	0	66.7	50	0	75
NRVM + Serum RNAseq	NF	3	33.3	13.6 [12.5–14.5]	0	0	0	0	0	0	0
	SV	3	33.3	1.9 [0.9–3.2]	100	66.7	0	100	66.7	0	66.7
Tissue RT-PCR	NF	7	57.1	7 [2.3–7.7]	0	0	57.1	0	0	14.3	0
	SV	14	57.1	1.78 [0.8–3.6]	71.4	21.4	0	64.3	64.3	0	78.6
All Patients	NF	17	64.7	8.0 [3.1–13.6]	0	0	29.4	5.9	0	5.9	0
	SV	18	66.7	2.6 [0.9–4.8]	61.1	27.8	5.6	66.7	55.6	0	77.8

Aggregate characteristics for all patients included in this study. ACEi = angiotensin-converting enzyme inhibitor, PDEi = phosphodiesterase inhibitor.

^*Non-PDEi Inotrope includes: dopamine, dobutamine, epinephrine, norepinephrine.